Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
165 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Escherichia coli Infections - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H2 2016, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape. Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 31 and 24 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 14 molecules, respectively.Escherichia coli Infections. Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Escherichia coli Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Escherichia coli Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Escherichia coli Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Escherichia coli Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Escherichia coli Infections Overview 9 Therapeutics Development 10 Pipeline Products for Escherichia coli Infections - Overview 10 Pipeline Products for Escherichia coli Infections - Comparative Analysis 11 Escherichia coli Infections - Therapeutics under Development by Companies 12 Escherichia coli Infections - Therapeutics under Investigation by Universities/Institutes 14 Escherichia coli Infections - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Escherichia coli Infections - Products under Development by Companies 18 Escherichia coli Infections - Products under Investigation by Universities/Institutes 21 Escherichia coli Infections - Companies Involved in Therapeutics Development 22 Adenium Biotech ApS 22 Arsanis, Inc. 23 AstraZeneca Plc 24 AvidBiotics Corp 25 Cellceutix Corp 26 Debiopharm International SA 27 Emergent BioSolutions Inc 28 F. Hoffmann-La Roche Ltd 29 GangaGen Inc 30 Hsiri Therapeutics LLC 31 Johnson & Johnson 32 Melinta Therapeutics Inc 33 Merck & Co Inc 34 Microbiotix Inc 35 Nabriva Therapeutics AG 36 Navigen Pharmaceuticals, Inc. 37 Nosopharm SAS 38 Novabiotics Ltd 39 Omnia Molecular Ltd 40 Paratek Pharmaceuticals Inc 41 Pherecydes Pharma SA 42 Phico Therapeutics Ltd 43 Procarta Biosystems Limited 44 Sealife PHARMA GMBH 45 Sequoia Sciences Inc 46 Soligenix Inc 47 Syntiron LLC 48 Tetraphase Pharmaceuticals Inc 49 Varinel Inc 50 Escherichia coli Infections - Therapeutics Assessment 51 Assessment by Monotherapy Products 51 Assessment by Target 52 Assessment by Mechanism of Action 54 Assessment by Route of Administration 56 Assessment by Molecule Type 58 Drug Profiles 60 A-3APO - Drug Profile 60 AA-139 - Drug Profile 61 AM-8722 - Drug Profile 62 ASN-4 - Drug Profile 63 AvR2-V10 - Drug Profile 64 BC-7634 - Drug Profile 66 BC-9074 - Drug Profile 67 BC-9529 - Drug Profile 68 BC-9563 - Drug Profile 69 BIZ-20131 - Drug Profile 70 BIZ-20132 - Drug Profile 71 BIZ-20133 - Drug Profile 72 CA-824 - Drug Profile 73 CC-1807 - Drug Profile 74 Debio-1454 - Drug Profile 75 Drugs for Bacterial Infections - Drug Profile 76 dusquetide - Drug Profile 77 Escherichia coli (whole cell) vaccine - Drug Profile 82 Escherichia coli vaccine - Drug Profile 83 Escherichia coli vaccine - Drug Profile 84 ETEC [strain B7A] vaccine - Drug Profile 85 ETEC vaccine - Drug Profile 86 EV-035 - Drug Profile 87 GN-4474 - Drug Profile 89 GNEG SNARE - Drug Profile 90 HT-07 - Drug Profile 91 INX-201 - Drug Profile 92 JNJ-63871860 - Drug Profile 93 MBX-2319 - Drug Profile 95 MDN-0057 - Drug Profile 96 mirandamycin - Drug Profile 98 NBTI-5463 - Drug Profile 99 NOSO-95179 - Drug Profile 100 NP-432 - Drug Profile 101 omadacycline tosylate - Drug Profile 102 Onc-72 - Drug Profile 108 P-100031 - Drug Profile 109 Peptides for Infectious Diseases - Drug Profile 110 PMX-100 - Drug Profile 111 PMX-1091 - Drug Profile 112 PMX-1142 - Drug Profile 113 PMX-1241 - Drug Profile 114 PMX-1278 - Drug Profile 115 PMX-1363 - Drug Profile 116 PMX-1405 - Drug Profile 117 PMX-223 - Drug Profile 118 PMX-229 - Drug Profile 119 PMX-247 - Drug Profile 120 PMX-633 - Drug Profile 121 PMX-668 - Drug Profile 122 PMX-693 - Drug Profile 123 PMX-843 - Drug Profile 124 PP-0121 - Drug Profile 125 Proteins for Infectious Diseases - Drug Profile 127 PT-5 - Drug Profile 128 Recombinant Protein for Escherichia Coli Infections - Drug Profile 129 RX-05 - Drug Profile 130 RXP-873 - Drug Profile 131 SE-1 - Drug Profile 132 Shigetec - Drug Profile 133 SLP-0901 - Drug Profile 134 SLP-0905 - Drug Profile 135 Small Molecule for Malaria and Bacterial Infections - Drug Profile 136 Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 137 Small Molecules for Bacterial Infections and Lung Infection - Drug Profile 138 Small Molecules for Escherichia Coli Infections - Drug Profile 139 Small Molecules for Escherichia coli Infections - Drug Profile 140 Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 141 Small Molecules to Inhibit 16S rRNA, Topoisomerases II and IV for Bacterial Infections - Drug Profile 142 Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections - Drug Profile 143 Small Molecules to Inhibit RecA for Bacterial Infections - Drug Profile 144 SPR-741 - Drug Profile 145 Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 146 Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 147 Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 148 Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections - Drug Profile 149 Synthetic Peptides for Escherichia Coli Infections - Drug Profile 150 TP-6076 - Drug Profile 151 VAR-10100 - Drug Profile 152 Escherichia coli Infections - Dormant Projects 153 Escherichia coli Infections - Discontinued Products 156 Escherichia coli Infections - Product Development Milestones 157 Featured News & Press Releases 157 Appendix 159 Methodology 159 Coverage 159 Secondary Research 159 Primary Research 159 Expert Panel Validation 159 Contact Us 159 Disclaimer 160
List of Tables
Number of Products under Development for Escherichia coli Infections, H2 2016 15 Number of Products under Development for Escherichia coli Infections - Comparative Analysis, H2 2016 16 Number of Products under Development by Companies, H2 2016 17 Number of Products under Development by Companies, H2 2016 (Contd..1) 18 Number of Products under Investigation by Universities/Institutes, H2 2016 20 Comparative Analysis by Clinical Stage Development, H2 2016 21 Comparative Analysis by Early Stage Development, H2 2016 22 Products under Development by Companies, H2 2016 23 Products under Development by Companies, H2 2016 (Contd..1) 24 Products under Development by Companies, H2 2016 (Contd..2) 25 Products under Investigation by Universities/Institutes, H2 2016 26 Escherichia coli Infections - Pipeline by Adenium Biotech ApS, H2 2016 27 Escherichia coli Infections - Pipeline by Arsanis, Inc., H2 2016 28 Escherichia coli Infections - Pipeline by AstraZeneca Plc, H2 2016 29 Escherichia coli Infections - Pipeline by AvidBiotics Corp, H2 2016 30 Escherichia coli Infections - Pipeline by Cellceutix Corp, H2 2016 31 Escherichia coli Infections - Pipeline by Debiopharm International SA, H2 2016 32 Escherichia coli Infections - Pipeline by Emergent BioSolutions Inc, H2 2016 33 Escherichia coli Infections - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 34 Escherichia coli Infections - Pipeline by GangaGen Inc, H2 2016 35 Escherichia coli Infections - Pipeline by Hsiri Therapeutics LLC, H2 2016 36 Escherichia coli Infections - Pipeline by Johnson & Johnson, H2 2016 37 Escherichia coli Infections - Pipeline by Melinta Therapeutics Inc, H2 2016 38 Escherichia coli Infections - Pipeline by Merck & Co Inc, H2 2016 39 Escherichia coli Infections - Pipeline by Microbiotix Inc, H2 2016 40 Escherichia coli Infections - Pipeline by Nabriva Therapeutics AG, H2 2016 41 Escherichia coli Infections - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 42 Escherichia coli Infections - Pipeline by Nosopharm SAS, H2 2016 43 Escherichia coli Infections - Pipeline by Novabiotics Ltd, H2 2016 44 Escherichia coli Infections - Pipeline by Omnia Molecular Ltd, H2 2016 45 Escherichia coli Infections - Pipeline by Paratek Pharmaceuticals Inc, H2 2016 46 Escherichia coli Infections - Pipeline by Pherecydes Pharma SA, H2 2016 47 Escherichia coli Infections - Pipeline by Phico Therapeutics Ltd, H2 2016 48 Escherichia coli Infections - Pipeline by Procarta Biosystems Limited, H2 2016 49 Escherichia coli Infections - Pipeline by Sealife PHARMA GMBH, H2 2016 50 Escherichia coli Infections - Pipeline by Sequoia Sciences Inc, H2 2016 51 Escherichia coli Infections - Pipeline by Soligenix Inc, H2 2016 52 Escherichia coli Infections - Pipeline by Syntiron LLC, H2 2016 53 Escherichia coli Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2016 54 Escherichia coli Infections - Pipeline by Varinel Inc, H2 2016 55 Assessment by Monotherapy Products, H2 2016 56 Number of Products by Stage and Target, H2 2016 58 Number of Products by Stage and Mechanism of Action, H2 2016 60 Number of Products by Stage and Route of Administration, H2 2016 62 Number of Products by Stage and Molecule Type, H2 2016 64 Escherichia coli Infections - Dormant Projects, H2 2016 158 Escherichia coli Infections - Dormant Projects (Contd..1), H2 2016 159 Escherichia coli Infections - Dormant Projects (Contd..2), H2 2016 160 Escherichia coli Infections - Discontinued Products, H2 2016 161
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
